Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

Data show people with pulmonary arterial hypertension tend to stay in the hospital longer and have higher medical bills.

Implementing the ventilator-associated events (VAE) prevention protocol at Community Health Network has yielded remarkable ...

Most online pulmonary rehabilitation videos are understandable but lack key disease-specific information for conditions other than COPD.

SAN DIEGO - Gossamer Bio, Inc. (NASDAQ: GOSS) saw its shares climb 5.4% after the biopharmaceutical company reported better-than-expected fourth quarter results and provided updates on its pulmonary ...

Boosting MTMR7 production reversed signs of pulmonary arterial hypertension in a mouse model of PAH and may serve as a ...

After transcatheter patent foramen ovale (PFO) closure, patients with nickel hypersensitivity were more likely to develop ...

Safety of a Potential New Treatment to Manage Complications from Sickle Cell Disease Apr. 11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing ...

West Virginia — 69.6% Louisiana — 62.5% Tennessee — 62.1% Arkansas — 61.8% Alabama — 61.6% Maine — 61.1% Michigan — 60.3% Oklahoma — 60.1% Ohio — 59.9% Oregon — 59.7% ...

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the ...

When it comes to health, low-income rural communities in Ohio and elsewhere face a double whammy: residents tend to be sicker ...